Should You Invest In Bitcoin, ETFs, Or Bitcoin Treasury Companies?
There Are No Solutions, Only Trade-Offs' - Thomas Sowell
After many years of regulatory resistance to Bitcoin, the asset has now gained approval to enter into mainstream capital markets. Starting with the approval of spot BTC ETFs to trade on January 11, 2024, various legal wrappers for BTC exposure have emerged.
Recently, a notable trend has emerged as public companies add BTC to their balance sheets. Many investors likely wonder how to get best involved with this complex set of options. There are no black-and-white answers to this, only trade-offs.
In this article, we will break down the pros and cons of each.
Real BTC
Owning actual Bitcoin, held in a personally controlled wallet of your own custody, is the original form of owning Bitcoin. Much like owning a bar of gold in your house, this offers complete control over the asset. This was the original intent of Bitcoin, an asset independent of government control or centralized authority. If custodied properly, it can not be seized or hacked or, potentially, even known that you own it.
Self-custody offers a double-edged sword for many. Properly custodying Bitcoin in cold storage can result in a complete loss of your investment if not done carefully. First, the private key can be lost and unrecoverable. This famously occurred to James Howells, who accidentally disposed of the private key to access 8000 BTC, worth over $850MM today. There is no back-up for self-custody. Just as if you lost a bar of gold, it can be lost forever with no recourse. With great power comes great responsibility. In addition, ease of access to cold storage Bitcoin means that transacting may be slow. The process of accessing, transferring, or selling Bitcoin can take hours or days, which may pose a problem for some.
There are alternatives to this, but they essentially remove the benefit of owning BTC directly. This includes keeping your Bitcoin on an exchange, storing your private keys in a bank or with a lawyer, or using a private key device like a Ledger to store them. This decreases the odds of you losing your Bitcoin; it also removes the self-sovereign properties that make owning Bitcoin attractive and unique. You have to trust some other party or company to keep you secure.
ETFs
Bitcoin ETFs are legal wrappers that allow people to gain exposure to the price of Bitcoin. They create a legal entity that holds the Bitcoin in custody on your behalf. The ETFs are regulated by the SEC and must abide by strict compliance, reporting, and security standards to be approved. This allows regular investors to make an investment in Bitcoin without having to deal with the technological peculiarities the asset poses. These ETFs are trading on major stock exchanges and can also be accessed by retirement accounts and large financial institutions that must abide by strict investment and regulatory policies.
Though ETFs simplify ownership, they also neuter much of the unique protections Bitcoin can provide. You are depending on a large set of human beings to protect you. This includes the ETF creator, a firm like BlackRock or Fidelity, for example, the custodian, which is almost always Coinbase, the regulators, and market-making firms. Though all of these groups are regulated and legitimate, their incentives are not exactly aligned with every individual who wants to own bitcoin. Changes to policy, technical errors, hacks, and fraud can all arise when so many counterparties get involved.
BTC Treasury Companies
The latest wave of BTC exposure has come in the form of so-called Bitcoin Treasury Companies. These are public companies that hold Bitcoin rather than only USD. These vehicles offer many of the regulated protections and mainstream accessibility of an ETF and can be traded on exchanges, but add a variety of strategies and financial engineering approaches to aim to generate greater returns.
These approaches can vary widely depending on the company. It can include selling more shares of stock into the market to raise more money, selling convertible debt, offering exposure across different jurisdictions in order to tap into untouched markets, trading the bitcoin using derivatives, taking out loans with the bitcoin to buy more bitcoin, and much more. For some jurisdictions, no ETF exists, and so a simple company that just buys and holds Bitcoin for shareholders may be the best option available. All of this adds another layer of human involvement to the risk of the investment. It can also mean much greater upside if chosen properly. Some of these companies trade at 10 times the value of the actual Bitcoin they hold.
Though investors may be able to make more upside with BTC treasury companies, gaining exposure to intelligent strategies and retail buying momentum, they also have more risk. The same factors that can create outsized gains can create outsized losses. These are very sophisticated financial products that leverage aspects of retail speculation, debt instruments, marketing, and legal and jurisdictional arbitrage to, hopefully, outperform Bitcoin. Some of these strategies suffer from black swan-type risk, in which they will look to be doing very well until they suddenly fail. Others will be successful far out into the future.
One important aspect to consider with BTC Treasury Companies is whether they are pure-play Bitcoin holding companies or does the Bitcoin complement other business activity and income. Companies that have real income may be better positioned in the long run for stability and risk management during times when the price of BTC falters, since they have other ways to pay bills and stay in business. Companies that are pure-play vehicles may have greater upside and volatility.
In the end, all of these vehicles can make sense for different types of investors, from long-term individual holders to pension funds to day traders. It's important to truly understand what the company does to generate a return for you so that you can evaluate risk with a clear perspective.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
The No. 1 Cost Threatening Your Retirement Savings
Insurance costs have skyrocketed since the pandemic — and show few signs of slowing down. That makes it hard to plan for costs in retirement, as the goalposts keep moving. For You: Trending Now: Keep an eye on these three insurance costs in particular as you plan your retirement nest egg. Supplemental Medicare Coverage Yes, retirees become eligible for Medicare coverage at 65. However, it doesn't cover everything. 'The average American spends nearly $200,000 on healthcare expenses during their golden years,' noted Whitney Stidom, vice president of consumer enablement at eHealth Insurance. In fact, a 2025 study by the Employee Benefit Research Institute found that some couples need up to $428,000 to have a 90% chance of covering their healthcare costs in retirement. A new survey from eHealth found 76% of people underestimate (or don't know) the average cost of healthcare in retirement. 'Enrolling in Medicare Advantage is often affordable, and will limit maximum out-of-pocket costs for the year,' said Stidom. 'Plus, most Advantage plans come with prescription drug coverage. Some Medicare Advantage plans come with special benefits like discounted gym memberships, coverage for over-the-counter drugs and more.' To help prepare in advance for unpredictable healthcare and supplemental Medicare coverage costs, consider opening a health savings account (HSA). They offer the best tax benefits of any tax-advantaged account, as you can deduct the contributions, they compound tax-free, and you pay no taxes on withdrawals. I'm a Financial Expert: Long-Term Care Insurance Medicare doesn't cover long-term care — but it gets expensive, and fast. The '2025 Trends in Retirement Planning' study by the Journal of Financial Planning found that 40.7% of retirees carry long-term care insurance, and 44.9% pay for a rider on other insurance products. Unlike working people, retirees can't increase their income to offset rising costs. When insurance rates go up, retirees have to cut spending elsewhere to stay afloat — which can quickly downgrade their quality of life. Homeowners Insurance The last few years have not been kind to homeowners insurance clients. 'Currently the average homeowner is paying $2,802 for home insurance,' explained Susan Meyer, insurance analyst at The Zebra. 'In 2024, the average was $1,602 for the same coverage — a 74% increase in only a year.' Granted, most homeowners aren't actually paying 74% more for their policies after just one year. Many have downgraded coverage or increased their deductible just to afford policies at the new rates. Homeowners insurance may play a larger role in where Americans choose to retire in the coming years. Already, three of the four states with the oldest populations (Maine, West Virginia, Vermont and Florida) have below-average homeowners insurance premiums. Meyer noted that the exception, Florida, has an average premium of $3,333 given the high frequency of storm damage. Similarly, climate scientist Max Dugan-Knight at Deep Sky Research pointed to fire-prone areas in California, Oregon and Texas where private insurers have stopped issuing coverage altogether. 'State-backed FAIR plans and federal flood insurance program end up billing taxpayers rather than addressing the root problem that some homes are uninsurable,' he said. 'That forces all taxpayers to subsidize the few who live in the highest risk areas.' As you plan your retirement, consider factoring in insurance risk. Some higher-risk areas may become impractical to insure in the years to come. More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 Here's the Minimum Salary Required To Be Considered Upper Class in 2025 7 Things You'll Be Happy You Downsized in Retirement This article originally appeared on The No. 1 Cost Threatening Your Retirement Savings Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Rush Enterprises (NASDAQ:RUSH.A) Might Have The Makings Of A Multi-Bagger
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. With that in mind, we've noticed some promising trends at Rush Enterprises (NASDAQ:RUSH.A) so let's look a bit deeper. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. What Is Return On Capital Employed (ROCE)? For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for Rush Enterprises: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.15 = US$449m ÷ (US$4.7b - US$1.7b) (Based on the trailing twelve months to March 2025). Thus, Rush Enterprises has an ROCE of 15%. On its own, that's a standard return, however it's much better than the 11% generated by the Trade Distributors industry. See our latest analysis for Rush Enterprises In the above chart we have measured Rush Enterprises' prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free analyst report for Rush Enterprises . The Trend Of ROCE Rush Enterprises is displaying some positive trends. Over the last five years, returns on capital employed have risen substantially to 15%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 58%. This can indicate that there's plenty of opportunities to invest capital internally and at ever higher rates, a combination that's common among multi-baggers. What We Can Learn From Rush Enterprises' ROCE All in all, it's terrific to see that Rush Enterprises is reaping the rewards from prior investments and is growing its capital base. Since the stock has returned a staggering 154% to shareholders over the last five years, it looks like investors are recognizing these changes. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence. On a separate note, we've found 1 warning sign for Rush Enterprises you'll probably want to know about. For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless. Eli Lilly and Novartis have taken steps to mitigate the potential impact. Both drugmakers are innovative, deliver strong financial results, and have excellent dividends. 10 stocks we like better than Eli Lilly › President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country. Although there were hopes that certain sectors would be spared -- including healthcare -- it turns out that won't be the case. Higher duties on imports could increase companies' costs, which would squeeze their margins and bottom lines, and meaningfully hurt their stock performance. However, even with this threat, there are still some healthcare companies worth investing in, including Eli Lilly (NYSE: LLY) and Novartis (NYSE: NVS). 1. Eli Lilly Eli Lilly has been expanding its U.S.-based manufacturing capacity for years, but it has recently accelerated this effort. The pharmaceutical leader has now invested, or committed to invest, $50 billion to build or update manufacturing sites in the country since 2020, about half of which it announced during the first quarter. According to management, once it completes its ongoing projects, it will be able to manufacture 100% of medicines aimed at U.S. patients within the country while also increasing its exports. In other words, the drugmaker will be mostly insulated from the impact of Trump's tariffs. And there are other reasons to invest in Eli Lilly. Here are three: First, the company has demonstrated remarkable innovation in its core areas of diabetes and obesity in recent years. Its newer launches, Mounjaro and Zepbound, are already generating billions and allowing it to grow its revenue and earnings at a good rate. In the first quarter, its top line rose 45% year over year to $12.7 billion. Net income was $2.8 billion, 23% higher than the year-ago period. Results like these should be the norm in the next five years at least. Second, the company has an extensive pipeline. Lilly recently reported positive phase 3 results for an oral GLP-1 candidate, orforglipron. This was an important win for the company since its current GLP-1 medicines are administered subcutaneously, so orforglipron could attract some patients who want a more convenient option. And there are many other exciting candidates, even beyond diabetes and obesity care. Third, the company is an excellent dividend stock, despite its unimpressive forward yield of 0.8%. It has increased its payout by 102.7% in the past five years. But whether you seek growth or income, Eli Lilly is a top stock to buy now and hold for a long time, despite the threat of tariffs. 2. Novartis Novartis is following a similar blueprint to mitigate the impact of tariffs. The company announced it would invest $23 billion in the next five years to improve its U.S.-based manufacturing footprint. Although its results may suffer somewhat from the impact of tariffs in the meantime, the company should eventually be able to handle them, assuming the tariffs continue. It's another excellent healthcare stock to consider in this environment, particularly given its strong financial results and promising prospects. In the first quarter, net sales increased by 12% to $13.2 billion year over year. Net income was $4.5 billion, 22% higher than the year-ago period. Some might point out that Novartis is losing U.S. patent exclusivity for its heart failure medicine Entresto this year. In the first quarter, it was still its top-selling drug, generating $2.3 billion in sales, 20% higher than the prior-year quarter. This will be a significant loss, but management has prepared for it. Newer medicines should eventually replace Entresto, including Fabhalta, which treats paroxysmal nocturnal hemoglobinuria (a rare blood disease), and cancer drugs Scemblix and Pluvicto. All of them first earned approval in the U.S. between 2021 and 2023. In the first quarter, Pluvicto, the best-selling of the trio, generated revenue of $371 million, a 20% year-over-year increase. Furthermore, Novartis' deep pipeline will lead to even more launches. The company currently has over 100 ongoing programs. Lastly, Novartis is also a strong income stock. The drugmaker has increased its dividend for 28 consecutive years and currently offers a forward yield of 3.3%, significantly higher than the S&P 500's average yield of 1.3%. It should deliver solid returns for patient investors, despite an upcoming major patent cliff and potential impacts from tariffs. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Eli Lilly. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
